CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

BACKGROUND: Androgen deprivation therapy (ADT) is still the first-line treatment of prostate cancer (PCa). However, after a certain period of therapy, primary PCa inevitably progresses into castration-resistant PCa (CRPC). Enzalutamide (Enz) is an androgen receptor (AR) signal inhibitor which can de...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Wu, Yechen, Wang, Xinan, Xu, Chengdang, Wang, Licheng, Jian, Jingang, Wu, Denglong, Wu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250190/
https://www.ncbi.nlm.nih.gov/pubmed/35780240
http://dx.doi.org/10.1186/s40001-022-00730-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250190/
https://www.ncbi.nlm.nih.gov/pubmed/35780240
http://dx.doi.org/10.1186/s40001-022-00730-y

Ejemplares similares